Name | Value |
---|---|
Revenues | 2.5M |
Cost of Revenue | 0.0M |
Gross Profit | 2.5M |
Operating Expense | 163.9M |
Operating I/L | -161.4M |
Other Income/Expense | -11.6M |
Interest Income | 7.6M |
Pretax | -173.0M |
Income Tax Expense | 0.1M |
Net Income/Loss | -173.1M |
Arrowhead Pharmaceuticals, Inc. develops RNA interference (RNAi) therapeutic candidates for the treatment of liver diseases, hypertriglyceridemia, chronic obstructive pulmonary disorder, muscular dystrophy, gout, and COVID-19. The company's products in pipeline include ARO-AAT, ARO-APOC3, ARO-ANG3, ARO-HSD, ARO-ENaC, ARO-C3, ARO-Lung2, ARO-DUX4, ARO-XDH, ARO-COV, and ARO-HIF2. Additionally, Arrowhead is involved in the development of JNJ-3989 for chronic hepatitis B virus infection, Olpasiran to reduce apolipoprotein A production, and ARO-AMG1 for genetically validated cardiovascular targets.